GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics sold by majority-owned joint venture ViiV Healthcare, which helped ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

The company has placed a strong emphasis on expanding its cancer drug portfolio and specialty medicines. However, GSK's latest financial report comes amid a barrage of lawsuits, including a major ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...